Basit öğe kaydını göster

dc.contributor.authorChabblani, Jay
dc.contributor.authorHindi, Isaac
dc.contributor.authorAgrawal, Kushal
dc.contributor.authorLowenstein, Anat
dc.contributor.authorRehak, Matus
dc.contributor.authorBusch, Catharina
dc.contributor.authorIglicki, Matias
dc.contributor.authorZur, Dinah
dc.contributor.authorFraser-Bell, Samantha
dc.contributor.authorLains, Ines
dc.contributor.authorSantos, Ana Rita
dc.contributor.authorLupidi, Marco
dc.contributor.authorCagini, Carlo
dc.contributor.authorGabriel, Pierre-Henry
dc.contributor.authorCouturier, Aude
dc.contributor.authorMané-Tauty, Valerie
dc.contributor.authorGiancopoli, Ermete
dc.contributor.authorD’Amico Ricci , Giuseppe
dc.contributor.authorCebeci, Zafer
dc.contributor.authorRodríguez-Valdés , Patricio J
dc.contributor.authorChaikitmongkol, Voraporn
dc.contributor.authorAmphornphruet, Atchara
dc.date.accessioned2021-12-10T12:29:06Z
dc.date.available2021-12-10T12:29:06Z
dc.identifier.citationBusch C., Iglicki M., Zur D., Fraser-Bell S., Lains I., Santos A. R. , Lupidi M., Cagini C., Gabriel P., Couturier A., et al., "Was tun bei therapierefraktärem diabetischen Makulaödem nach anti-VEGF loading dosis? Fortsetzung der anti-VEGF Therapie versus früher Wechsel zu Dexamethason Implantat – Real-Life Daten.", DOG 2018, Bonn, Almanya, 27 - 30 Eylül 2018, ss.68
dc.identifier.othervv_1032021
dc.identifier.otherav_bfacd740-9cec-4977-8103-315e9306d6ae
dc.identifier.urihttp://hdl.handle.net/20.500.12627/173983
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.titleWas tun bei therapierefraktärem diabetischen Makulaödem nach anti-VEGF loading dosis? Fortsetzung der anti-VEGF Therapie versus früher Wechsel zu Dexamethason Implantat – Real-Life Daten.
dc.typeBildiri
dc.contributor.department, ,
dc.contributor.firstauthorID2645509


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster